A Phase 1 interventional study of CC-92480 and Placebo in Healthy Volunteers, sponsored by Celgene. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-10.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 1 study that will be conducted in 2 parts. Participants may participate in 1 part only.
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
First submitted after Celgene became part of Bristol-Myers Squibb.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must satisfy the following criteria to be enrolled in the study:
For males:
a. Practice true abstinence (which must be reviewed on a monthly basis, as applicable) or agree to use a barrier not made of natural (animal) membrane (eg, latex or polyurethane condoms are acceptable) when engaging in sexual activity with a female of (FCBP) while on study medication, and for at 3 months after the last dose of study medication even if he has undergone a successful vasectomy.
For females:
Female participants must have been surgically sterilized (hysterectomy or bilateral oophorectomy; proper documentation required) at least 6 months before screening or be (defined as 24 months without menses before screening, with a serum follicle-stimulation hormone (FSH) level of > 40 IU/L at screening.
Exclusion Criteria:
The presence of any of the following will exclude a participant from enrollment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CC-92480-02 (Formulation A) or matching placebo to be administered orally under fasted conditions.
Drug: CC-92480 · Other: Placebo
A single oral dose of CC-92480 (Formulation B) administered under fasted conditions.
Drug: CC-92480
A single oral dose of CC-92480-02 (Formulation A) administered under fasted conditions.
Drug: CC-92480
A single oral dose of CC-92480 (Formulation B) administered under fed conditions (low-fat meal).
Drug: CC-92480
A single oral dose of CC-92480-02 (Formulation A) administered under fed conditions (high-fat meal).
Drug: CC-92480
Oral
Oral
Pharmacokinetics- Cmax Part 1
Maximum plasma concentration of drug
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Tmax Part 1
Time to maximum plasma concentration
Time frame: Up to 96 hours after dosing
Pharmacokinetics- AUC0-∞Part 1
Area under the plasma concentration-time curve from time zero to infinity
Time frame: Up to 96 hours after dosing
Pharmacokinetics- AUC0-t Part1
Area under the plasma concentration-time curve from time zero to the last observable concentration
Time frame: Up to 96 hours after dosing
Pharmacokinetics- t½ Part 1
Terminal elimination half-life
Time frame: Up to 96 hours after dosing
Pharmacokinetics- CL/F Part 1
Apparent total plasma clearance
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Vz/F Part 1
Apparent volume of distribution
Time frame: Up to 96 hours after dosing
Pharmacokinetics- tlag Part 1
Lag time between time of administration and start of absorption
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Cmax Part 2
Maximum plasma concentration of drug
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Ratio of Cmax (Formulation A/Formulation B) Part 2
Ratio of maximum plasma concentration of drug
Time frame: Up to 96 hours after dosing
Pharmacokinetics- AUC0-∞ Part 2
Area under the plasma concentration-time curve from time zero to infinity
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Ratio of AUC0-∞ (Formulation A/Formulation B) Part 2
Ratio of area under the plasma concentration-time curve from time zero to infinity
Time frame: Up to 96 hours after dosing
Pharmacokinetics- AUC0-t Part 2
Area under the plasma concentration-time curve from time zero to the last observable concentration
Time frame: Up to 96 hours after dosing
Pharmacokinetics- AUC0-t (Formulation A/Formulation B) Part 2
Area under the plasma concentration-time curve from time zero to the last observable concentration
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Tmax Part 2
Time to maximum plasma concentration
Time frame: Up to 96 hours after dosing
Pharmacokinetics- t½ Part 2
Terminal elimination half-life
Time frame: Up to 96 hours after dosing
Pharmacokinetics- CL/F Part 2
Apparent total plasma clearance
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Vz/F Part 2
Apparent volume of distribution
Time frame: Up to 96 hours after dosing
Pharmacokinetics- tlag Part 2
Lag time between time of administration and start of absorption
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Cmax (high-fat meal)
Maximum plasma concentration of drug
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Ratio (Fed/Fasted) of Cmax (high-fat meal)
Ratio of maximum plasma concentration of drug
Time frame: Up to 96 hours after dosing
Pharmacokinetics- AUC0-∞(high-fat meal)
Area under the plasma concentration-time curve from time zero to infinity
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Ratio (Fed/Fasted) of AUC0-∞ (high-fat meal)
Ratio of area under the plasma concentration-time curve from time zero to infinity
Time frame: Up to 96 hours after dosing
Pharmacokinetics- AUC0-t (high-fat meal)
Area under the plasma concentration-time curve from time zero to the last observable concentration
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Ratio (Fed/Fasted) of AUC0-t (high-fat meal)
Ratio of area under the plasma concentration-time curve from time zero to the last observable concentration
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Tmax (high-fat meal)
Time to maximum plasma concentration
Time frame: Up to 96 hours after dosing
Pharmacokinetics- AUC0-24 (high-fat meal)
Area under the plasma concentration-time curve from time zero to 24 hours post dose
Time frame: Up to 96 hours after dosing
Pharmacokinetics- t½ (high-fat meal)
Terminal elimination half-life
Time frame: Up to 96 hours after dosing
Pharmacokinetics- CL/F (high-fat meal)
Apparent total plasma clearance
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Vz/F (high-fat meal)
Apparent volume of distribution
Time frame: Up to 96 hours after dosing
Pharmacokinetics- tlag (high-fat meal)
Lag time between time of administration and start of absorption
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Cmax (low-fat meal)
Maximum plasma concentration of drug
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Ratio (Fed/Fasted) of Cmax (low-fat meal)
Ratio of maximum plasma concentration of drug
Time frame: Up to 96 hours after dosing
Pharmacokinetics- AUC0-∞(low-fat meal)
Area under the plasma concentration-time curve from time zero to infinity
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Ratio (Fed/Fasted) of AUC0-∞(low-fat meal)
Ratio of area under the plasma concentration-time curve from time zero to infinity
Time frame: Up to 96 hours after dosing
Pharmacokinetics- AUC0-t (low-fat meal)
Area under the plasma concentration-time curve from time zero to the last observable concentration
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Ratio (Fed/Fasted) of AUC0-t (low-fat meal)
Ratio of area under the plasma concentration-time curve from time zero to the last observable concentration
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Tmax (low-fat meal)
Time to maximum plasma concentration
Time frame: Up to 96 hours after dosing
Pharmacokinetics- t½ (low-fat meal)
Terminal elimination half-life
Time frame: Up to 96 hours after dosing
Pharmacokinetics- CL/F (low-fat meal)
Apparent total plasma clearance
Time frame: Up to 96 hours after dosing
Pharmacokinetics- Vz/F (low-fat meal)
Apparent volume of distribution
Time frame: Up to 96 hours after dosing
Pharmacokinetics- tlag (low-fat meal)
Lag time between time of administration and start of absorption
Time frame: Up to 96 hours after dosing
Incidence of Adverse Events (AEs)
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.
Time frame: From enrollment until at least 28 days after completion of study treatment
Ran from Jan 2021 to primary completion in Oct 2021, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mezigdomide